Platelet VASP phosphorylation assessment in clopidogrel-treated patients: Lack of agreement between Western blot and flow cytometry

Platelets

Volumn 16, Issue 8, 2005, Pages 474-481

  Hezard, Nathalie ^a   Metz, Damien ^a,b   Garnotel, Roselyne ^b,c   Simon, Gerard ^a   Mace, Catherine ^a   Koebel, Pascale ^b   Nguyen, Philippe ^a,b  

^a SERVICE DE DERMATOLOGIE   (France)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^c CNRS   (France)

Author keywords

Flow cytometry; Platelets; Thienopyridines; VASP; Western blot

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PROSTAGLANDIN E1; PYRIDINE DERIVATIVE; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; ARTICLE; CALCULATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENSITIVITY ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; WESTERN BLOTTING;

AGED; BLOOD PLATELETS; BLOTTING, WESTERN; CELL ADHESION MOLECULES; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TICLOPIDINE;

EID: 30944457789     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100500212551     Document Type: Article

References (17)

1. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets. Definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999;82(3):1145-1152.
2. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler M. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003;59(3):295-302.
3. Schrör K, Weber AA, Hohlfeld T. Clopidogrel 'resistance'. Thromb Haemost 2004;92(2):229-231.
4. Müller I, Besta F, Schulz C, Massberg S, Schömig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89(5):783-787.
5. Taubert D, Kastrati A, Harlfinger S, Gorchakova O, Lazar A, von Beckerath N, Schömig A, Schömig E. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004;92(2):311-316.
6. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109(2):166-171.
7. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003;108(8):989-995.
8. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidin in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;02:624-629.
9. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Clopidogrel in unstable angina to prevent recurrent events trial (CURE) investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527-533.
10. Steinhubl SR, Berger PB, Mann JT, Fry ET, Delago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomised controlled trial. J Am Med Assoc 2002;288(19):2411-2420.
11. Smolenski A, Bachmann C, Reinhard K, Hönig-Liedl P, Jarchau T, Hoschuetzky H, Walter U. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J Biol Chem 1998;273(32):20029-20035.
12. Horstrup K, Jablonka B, Hönig-Liedl P, Just M, Kochsiek K, Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem 1994;225(1):21-27.
13. Li Z, Adjic J, Eingenhaler M, Du X. A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans. Blood 2003;101(11):4423-4429.
14. Schäfer A, Burkhardt M, Vollkommer T, Bauersachs J, Münzel T, Walter U, Smolenski A. Endothelium-dependent and -independent relaxation and VASP serines 157/239 phosphorylation by cyclic nucleotide-elevating vasodilators in rat aorta. Biochem Pharmacol 2003;65(3):397-405.
15. Grossmann R, Sokolova O, Schnurr A, Bonz A, Porsche C, Obergfell A, Lengenfelder B, Walter U, Eigenthaler M. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004;92(6):1201-1206.
16. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005;3(1):85-92.
17. Kelsey JL, Thompson WD, Evans AS. Indices of reproducibility. In: Methods in observational epidemiology. Oxford: Oxford University Press 1986;10:288-292.